BNF:

13.6

Status:

Red

Decision Date:

June 2014

Comments

RED:^1,2,3 as per NICE TA180 for psoriasis

RED:^1,2,3 NICE TA340 for treating active psoriatic arthritis. (Decision date - July 2015)

RED^1,2,3: NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people. (Decision date - August 2017)

RED^1,2,3: NICE TA456: ustekinumab for moderately to severely active Crohn's Disease after previous treatment.

RED ^1,2,3: NICE TA633: ustekinumab for moderately to severely active ulcerative colitis (Decision date - July 2020)

 

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again